If your child has a rare disease, you've probably spent hundreds of hours researching treatments, clinical trials, genetic mutations, specialists. You know the drug names. You know the pharma companies. You might even know the principal investigators by name. There's a piece of the puzzle, though, that almost no parent talks about, because it sounds like policy wonk territory: the FDA's Priority Review Voucher program.
Here's why it matters to you directly. Without this program, there's a good chance the drug your child takes (or the one in a trial you're watching) would never have been developed at all.
What Is an FDA Priority Review Voucher?
When a pharmaceutical company develops a drug for a rare pediatric disease and gets FDA approval, the agency hands them something called a priority review voucher. It's essentially a golden ticket. The company can use it on any future drug they submit to the FDA, and instead of waiting the standard 10-12 months for the agency to review that drug, the review happens in about 6 months. Four months faster.
Four months might not sound like much. For a blockbuster drug that could generate billions in revenue, though, getting to market 4 months earlier is worth an enormous amount of money. So these vouchers are valuable. Really valuable.
The company doesn't have to use the voucher themselves. They can sell it. They do.
How Priority Review Vouchers Incentivize Rare Disease Drug Development
This is the question at the center of everything. Developing a new drug costs somewhere between $1 billion and $2.6 billion, depending on who's counting and what you include. A rare pediatric disease might affect a few thousand people worldwide. The math doesn't work. A company could spend a decade and a billion dollars to develop a drug that generates $50 million a year in sales. No investor signs up for that.
The voucher changes the equation. If a company knows they'll get a voucher worth $100 million or more upon approval, the economics shift. That's not charity. It's not a grant. It's a market-based incentive that says: develop something for a tiny patient population, and we'll give you a tradeable asset you can cash in elsewhere.
Does it work? The evidence is mixed. The Government Accountability Office interviewed 7 drug sponsors. Of those, 6 called the voucher one of a number of factors in their development decisions, and 1 called it pivotal (GAO, 2020). The same report found the few published studies showed little or no effect on drug development.
Rare Disease Drugs Made Possible by Priority Review Vouchers
The voucher program isn't abstract. It's connected to treatments that real families depend on right now.
Daybue (trofinetide) for Rett syndrome. Acadia Pharmaceuticals received a voucher when it was approved in 2023, then sold that voucher to another company for $150 million. Rett syndrome affects roughly 1 in 10,000 girls. Before Daybue, there was no FDA-approved treatment targeting the condition's core symptoms. The voucher didn't single-handedly make Daybue possible, but it improved the financial case at a time when the company was deciding where to invest.
Elevidys for Duchenne muscular dystrophy. Sarepta's gene therapy received accelerated approval in 2023. The voucher awarded alongside it became part of Sarepta's broader financial strategy for a drug that costs $3.2 million per patient. In November 2025 the FDA added a boxed warning for serious liver injury and liver failure and limited Elevidys to patients who can still walk.
Zolgensma for spinal muscular atrophy. Novartis received a voucher when this gene therapy was approved in 2019. At $2.1 million per dose, Zolgensma was the most expensive drug in the world at the time. The voucher added another layer of return on what had been an enormously risky investment in a rare disease.
“AbbVie paid a record $350 million for a single priority review voucher in 2015, buying it from United Therapeutics. That price tag tells you how much faster FDA review is worth to a large pharma company.”
United Therapeutics announcement, August 2015
Priority Review Voucher Criticisms and Trade-Offs
Parents are practical people. When someone tells you a program is great, you want to know what the catch is. There are a few.
Vouchers reward FDA approval, not patient access
A company gets the voucher when the FDA approves their drug. That's the finish line for the incentive. What happens after, whether the drug is affordable, whether insurance covers it, whether patients can actually get it, that's a separate problem the voucher doesn't solve. Zolgensma costs $2.1 million. Elevidys costs $3.2 million. Approval and access are two different things, and the voucher only addresses the first.
Do some companies receive vouchers for drugs they would have developed anyway?
Critics argue that some companies receive vouchers for drugs they were already going to develop, making the voucher a windfall rather than a genuine incentive. This is hard to prove or disprove for any individual drug. The GAO found that 6 of the 7 sponsors it interviewed called the voucher one of several factors and only 1 called it pivotal, which fits either reading. There's no way to run the counterfactual.
Does buying a voucher let pharma companies skip the FDA line?
When a company buys a voucher for $200 million, they use it to speed up review of their own drug, which is often a mass-market product with nothing to do with rare diseases. Some critics point out that this effectively lets a company pay to cut in line at the FDA, potentially slowing down other reviews. The FDA charges the company that redeems a voucher an extra fee ($1,962,472 for fiscal year 2026) that's meant to offset the additional resources needed for faster review, but whether that fully covers the impact is debated.
Did the Rare Pediatric Disease Voucher Program Expire?
Congress created the rare pediatric disease priority review voucher program in 2012 as a temporary measure. It was supposed to expire. In December 2024, it did, at least for new drugs. After that the FDA could no longer give out the rare pediatric disease designation a drug needs to qualify. Drugs that already had it could still earn a voucher at approval, and some did, such as Abeona's Zevaskyn for a severe form of epidermolysis bullosa in April 2025.
During that gap, advocacy organizations and patient families pushed hard for reauthorization. The concern was straightforward: if companies can no longer count on receiving a voucher, the financial models that justified rare disease drug development start to fall apart. Pipeline decisions get revisited. Early-stage programs in rare pediatric diseases get shelved.
Congress revived the program on February 3, 2026, when the Consolidated Appropriations Act, 2026 became law. The FDA can now award these vouchers through September 30, 2029. The lapse itself revealed something important, though: the program's existence is not guaranteed, and families who depend on the drugs it incentivizes have a stake in whether it continues.
Will the FDA Make Priority Review Vouchers Permanent?
In its budget request for fiscal year 2027, released in spring 2026, the FDA asked Congress to make the rare pediatric disease priority review voucher program permanent. No more expiration dates. No more reauthorization battles. The agency's argument is simple: the cycle of expiration and renewal creates uncertainty that undermines the program's purpose. Companies making 10-year development decisions need to know the incentive will still exist when they reach the finish line.
If you're a parent whose child has a rare disease without a treatment, this proposal matters more than almost anything else happening in Washington right now. Permanent authorization means companies can plan around the voucher with confidence. It means fewer diseases fall through the cracks during gaps in funding. It means the next Daybue, the next Zolgensma, the next Elevidys is more likely to happen, not less.
What Priority Review Vouchers Mean for Clinical Trial Families
If your child's disease has an active clinical trial, the voucher program is working in the background. The company running that trial factored the potential voucher into their decision to invest in the program. It's baked into their financial projections, their board presentations, their investor decks. You'll never see it in a consent form or a trial listing on ClinicalTrials.gov, but it's there.
If your child's disease doesn't have a treatment or a trial yet, the voucher program represents one of the few levers that might change that. It won't fix everything. It won't make drug development fast or cheap or guarantee success. It shifts the calculus just enough, though, that a small biotech company might look at a disease affecting 2,000 kids and say: we can make this work.
63 vouchers for 47 diseases since 2012. That's 47 conditions where a company decided the investment was worth making. For the families affected, each one of those decisions changed everything.